Darbetin

Clinical Trials

Extensive clinical trials have evaluated darbepoetin alfa's efficacy and safety in various populations with anemia, including those with CKD and chemotherapy-induced anemia. Ongoing studies investigate its use in other conditions.

Lab Monitoring

• Hemoglobin (Hb) levels (monitor weekly or bi-weekly until stable, then monthly)
• Hematocrit
• Blood pressure (monitor regularly)
• Serum ferritin and transferrin saturation (TSAT) to assess iron status

Doctor Notes

• Monitor hemoglobin levels closely and adjust dose to maintain levels within the target range (e.g., 10-11 g/dL). Avoid exceeding 11 g/dL.
• Monitor blood pressure and manage hypertension effectively.
• Assess iron status before and during treatment; iron supplementation may be required.

Patient Guidelines

• Do not shake the syringe vigorously as this may denature the protein.
• Store in the refrigerator (2°C-8°C) in the original carton to protect from light. Do not freeze.
• Follow your doctor's instructions regarding dose and administration schedule.
• Report any new or worsening symptoms, especially high blood pressure or signs of blood clots.

Missed Dose Advice

If a dose is missed, administer it as soon as remembered. Then resume the usual dosing schedule. Do not administer a double dose to make up for a missed dose.

Driving Precautions

Darbepoetin alfa is not expected to affect the ability to drive or use machinery. However, patients should be aware of potential side effects like headache or seizures, and should avoid driving or operating machinery if these occur.

Lifestyle Advice

• Maintain a healthy diet, particularly one rich in iron if advised by your doctor.
• Regularly monitor blood pressure as advised by your healthcare provider.
• Engage in light physical activity as tolerated.